Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First Author:   Goldman et al. 

Journal/preprint name:  MedRxiv 

Tags:  Clinical-Case study, Immunology/Immunity 

Summary  

Goldman et al. define a new SARS-CoV-2 reinfection case by whole viral genome sequencing and correlate the lack of protection to weak humoral immune responseThis preprint describes a case-study from a patient that was found re-infected 140 days (March and July) after the first SARS-CoV-2 PCR positive test but found less severely ill in re-infection. Whole genome sequencing of the viruses indicated that first and second infection were not due to prolonged viral shedding but to 2 genetically distinct virus. Antibody responses were evaluated only after re-infection and poor responses were found against spike and RBD (receptor binding domain) with a rapid decay. Overall, this pre-print describes a rare case of re-infection and correlates it with a failure in humoral immune responses 

Research Highlights  

  1.  Description of a re-infection SARS-CoV-2 case after 140 days of the first infection 

  1. Whole genome sequence of the virus shows 2 genetically distinct virus, last with D614G mutation. 

  1. Poor anti-spike and anti-RBD antibody responses were found in the patient after re-infection 

  1. No evidence of antibodies blocking RBD-ACE2 binding 

Impact for COVID-19 research:  

  • It describes a case of re-infection and correlates it with profound defects in humoral immune responses. Helps to understand the immune correlates for humoral immunity that might prevent re-infection. 

Methodologies: 

  • Study TypePatient-case study 

  • Key Techniques: whole genome sequencing,   

Limitations: 

  • The authors attribute re-infection to a poor humoral response from the first infection but there is no proof to that, other than a general weak humoral immunity for this patient after re-infection.  

  • The authors link the re-infection to the fact that first generated immune responses can’t protect from re-infection of the now more circulating virus harbouring the D614G mutation. However, most studies show that antibodies against the Spike are able to neutralize WT and D614G viruses and therefore re-infection may be ascribed in this case to malfunctioning of the humoral immunity.